![Eli Lilly and Company logo](/static/img/stocks/lly.png) |
Eli Lilly and Company
LLY
|
$ 844.27
|
$ 760 B
|
$ 2.35 B
|
124.5
|
18.6
|
$ 6.8
|
![usa](/static/img/countries/usa.png) |
![Novo Nordisk A/S logo](/static/img/stocks/nvo.png) |
Novo Nordisk A/S
NVO
|
$ 77.87
|
$ 421 B
|
∙ |
∙ |
∙ |
∙ |
![danmark](/static/img/countries/danmark.png) |
![AbbVie logo](/static/img/stocks/abbv.png) |
AbbVie
ABBV
|
$ 192.87
|
$ 341 B
|
$ 13.7 B
|
58.6
|
6.4
|
$ 3.4
|
![usa](/static/img/countries/usa.png) |
![Nanobiotix S.A. logo](/static/img/stocks/nbtx.png) |
Nanobiotix S.A.
NBTX
|
$ 4.03
|
$ 286 B
|
∙ |
∙ |
∙ |
∙ |
![france](/static/img/countries/france.png) |
![BeiGene, Ltd. logo](/static/img/stocks/bgne.png) |
BeiGene, Ltd.
BGNE
|
$ 184.71
|
$ 251 B
|
$ -484 M
|
∙ |
∙ |
∙ |
![cayman-islands](/static/img/countries/cayman-islands.png) |
![Novartis AG logo](/static/img/stocks/nvs.png) |
Novartis AG
NVS
|
$ 105.43
|
$ 227 B
|
$ 10.7 B
|
14.3
|
∙ |
$ 5.8
|
![schweiz](/static/img/countries/schweiz.png) |
![Merck & Co. logo](/static/img/stocks/mrk.png) |
Merck & Co.
MRK
|
$ 83.01
|
$ 211 B
|
$ 2.77 B
|
14.1
|
4.0
|
$ 7.2
|
![usa](/static/img/countries/usa.png) |
![Genfit SA logo](/static/img/stocks/gnft.png) |
Genfit SA
GNFT
|
$ 4.13
|
$ 160 B
|
∙ |
∙ |
∙ |
∙ |
![france](/static/img/countries/france.png) |
![Pfizer logo](/static/img/stocks/pfe.png) |
Pfizer
PFE
|
$ 25.53
|
$ 144 B
|
$ 5.52 B
|
29.9
|
2.6
|
$ 0.9
|
![usa](/static/img/countries/usa.png) |
![Gilead Sciences logo](/static/img/stocks/gild.png) |
Gilead Sciences
GILD
|
$ 104.08
|
$ 130 B
|
$ 3.06 B
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Vertex Pharmaceuticals Incorporated logo](/static/img/stocks/vrtx.png) |
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 459.0
|
$ 118 B
|
$ 4.35 B
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![AstraZeneca PLC logo](/static/img/stocks/azn.png) |
AstraZeneca PLC
AZN
|
$ 73.57
|
$ 96.9 B
|
$ 3.67 B
|
47.0
|
7.9
|
$ 1.4
|
![britain](/static/img/countries/britain.png) |
![Regeneron Pharmaceuticals logo](/static/img/stocks/regn.png) |
Regeneron Pharmaceuticals
REGN
|
$ 673.6
|
$ 72.7 B
|
$ 4.49 B
|
20.0
|
6.5
|
$ 41.8
|
![usa](/static/img/countries/usa.png) |
![Zoetis logo](/static/img/stocks/zts.png) |
Zoetis
ZTS
|
$ 157.52
|
$ 71.5 B
|
$ 498 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Axon Enterprise logo](/static/img/stocks/axon.png) |
Axon Enterprise
AXON
|
$ 683.41
|
$ 50.7 B
|
$ 112 M
|
124.2
|
10.7
|
$ 1.8
|
![usa](/static/img/countries/usa.png) |
![Verona Pharma plc logo](/static/img/stocks/vrna.png) |
Verona Pharma plc
VRNA
|
$ 64.21
|
$ 40.7 B
|
$ -81.8 M
|
∙ |
∙ |
∙ |
![britain](/static/img/countries/britain.png) |
![Alexion Pharmaceuticals, Inc. logo](/static/img/stocks/alxn.png) |
Alexion Pharmaceuticals, Inc.
ALXN
|
$ 182.5
|
$ 40.3 B
|
$ 33.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Pulmatrix logo](/static/img/stocks/pulm.png) |
Pulmatrix
PULM
|
$ 7.73
|
$ 28.2 B
|
$ -18.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Zai Lab Limited logo](/static/img/stocks/zlab.png) |
Zai Lab Limited
ZLAB
|
$ 29.0
|
$ 28 B
|
$ -289 M
|
∙ |
∙ |
∙ |
![china](/static/img/countries/china.png) |
![BioNTech SE logo](/static/img/stocks/bntx.png) |
BioNTech SE
BNTX
|
$ 119.83
|
$ 27.2 B
|
∙ |
∙ |
∙ |
∙ |
![germany](/static/img/countries/germany.png) |
![argenx SE logo](/static/img/stocks/argx.png) |
argenx SE
ARGX
|
$ 639.41
|
$ 25 B
|
∙ |
∙ |
∙ |
∙ |
![niderland](/static/img/countries/niderland.png) |
![Legend Biotech Corporation logo](/static/img/stocks/legn.png) |
Legend Biotech Corporation
LEGN
|
$ 36.42
|
$ 18.7 B
|
∙ |
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![United Therapeutics Corporation logo](/static/img/stocks/uthr.png) |
United Therapeutics Corporation
UTHR
|
$ 370.58
|
$ 17.3 B
|
$ 1.22 B
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Incyte Corporation logo](/static/img/stocks/incy.png) |
Incyte Corporation
INCY
|
$ 70.42
|
$ 14.6 B
|
$ 600 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Royalty Pharma plc logo](/static/img/stocks/rprx.png) |
Royalty Pharma plc
RPRX
|
$ 32.36
|
$ 14.5 B
|
$ 1.1 B
|
12.6
|
5.5
|
$ 2.1
|
![usa](/static/img/countries/usa.png) |
![Genmab A/S logo](/static/img/stocks/gmab.png) |
Genmab A/S
GMAB
|
$ 21.3
|
$ 14 B
|
$ 5.56 B
|
0.6
|
2.7
|
$ 62.2
|
![danmark](/static/img/countries/danmark.png) |
![Intra-Cellular Therapies logo](/static/img/stocks/itci.png) |
Intra-Cellular Therapies
ITCI
|
$ 127.82
|
$ 12.3 B
|
$ -212 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![BioMarin Pharmaceutical logo](/static/img/stocks/bmrn.png) |
BioMarin Pharmaceutical
BMRN
|
$ 64.85
|
$ 12.2 B
|
$ 413 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Neurocrine Biosciences logo](/static/img/stocks/nbix.png) |
Neurocrine Biosciences
NBIX
|
$ 115.02
|
$ 11.5 B
|
$ 148 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Acceleron Pharma Inc. logo](/static/img/stocks/xlrn.png) |
Acceleron Pharma Inc.
XLRN
|
$ 179.68
|
$ 10.9 B
|
$ -60.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Alterity Therapeutics Limited logo](/static/img/stocks/athe.png) |
Alterity Therapeutics Limited
ATHE
|
$ 4.42
|
$ 10.6 B
|
∙ |
∙ |
∙ |
∙ |
![australia](/static/img/countries/australia.png) |
![Bio-Techne Corporation logo](/static/img/stocks/tech.png) |
Bio-Techne Corporation
TECH
|
$ 65.94
|
$ 10.4 B
|
$ 303 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Exelixis logo](/static/img/stocks/exel.png) |
Exelixis
EXEL
|
$ 35.0
|
$ 10.2 B
|
$ 262 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Sarepta Therapeutics logo](/static/img/stocks/srpt.png) |
Sarepta Therapeutics
SRPT
|
$ 107.95
|
$ 9.97 B
|
$ 45.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Jazz Pharmaceuticals plc logo](/static/img/stocks/jazz.png) |
Jazz Pharmaceuticals plc
JAZZ
|
$ 133.96
|
$ 8.48 B
|
$ 1.17 B
|
14.5
|
1.9
|
$ 8.3
|
![irlanda](/static/img/countries/irlanda.png) |
![Институт стволовых клеток человека logo](/static/img/stocks/iskj.png) |
Институт стволовых клеток человека
ISKJ
|
-
|
-
|
₽ -3.4 M
|
∙ |
∙ |
∙ |
![russia](/static/img/countries/russia.png) |
![Halozyme Therapeutics logo](/static/img/stocks/halo.png) |
Halozyme Therapeutics
HALO
|
$ 58.29
|
$ 7.69 B
|
$ 475 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Pharming Group N.V. logo](/static/img/stocks/phar.png) |
Pharming Group N.V.
PHAR
|
$ 9.2
|
$ 7.59 B
|
∙ |
∙ |
∙ |
∙ |
![niderland](/static/img/countries/niderland.png) |
![Corcept Therapeutics Incorporated logo](/static/img/stocks/cort.png) |
Corcept Therapeutics Incorporated
CORT
|
$ 72.72
|
$ 7.53 B
|
$ 109 M
|
34.2
|
7.9
|
$ 1.4
|
![usa](/static/img/countries/usa.png) |
![Cerevel Therapeutics Holdings logo](/static/img/stocks/default.png) |
Cerevel Therapeutics Holdings
CERE
|
$ 44.96
|
$ 7.29 B
|
$ -424 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Madrigal Pharmaceuticals logo](/static/img/stocks/mdgl.png) |
Madrigal Pharmaceuticals
MDGL
|
$ 337.2
|
$ 6.66 B
|
$ -380 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Axsome Therapeutics logo](/static/img/stocks/axsm.png) |
Axsome Therapeutics
AXSM
|
$ 131.15
|
$ 5.96 B
|
$ -265 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Alkermes plc logo](/static/img/stocks/alks.png) |
Alkermes plc
ALKS
|
$ 35.89
|
$ 5.94 B
|
$ 364 M
|
∙ |
∙ |
∙ |
![irlanda](/static/img/countries/irlanda.png) |
![Blueprint Medicines Corporation logo](/static/img/stocks/bpmc.png) |
Blueprint Medicines Corporation
BPMC
|
$ 93.94
|
$ 5.9 B
|
$ 14.8 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Abcam plc logo](/static/img/stocks/abcm.png) |
Abcam plc
ABCM
|
$ 23.99
|
$ 4.9 B
|
∙ |
∙ |
∙ |
∙ |
![britain](/static/img/countries/britain.png) |
![Aphria Inc. logo](/static/img/stocks/apha.png) |
Aphria Inc.
APHA
|
$ 15.38
|
$ 4.87 B
|
$ 2.32 B
|
∙ |
∙ |
∙ |
![canada](/static/img/countries/canada.png) |
![China Biologic Products Holdings, Inc. logo](/static/img/stocks/cbpo.png) |
China Biologic Products Holdings, Inc.
CBPO
|
$ 119.99
|
$ 4.65 B
|
$ 991 M
|
∙ |
∙ |
∙ |
![china](/static/img/countries/china.png) |
![Ionis Pharmaceuticals logo](/static/img/stocks/ions.png) |
Ionis Pharmaceuticals
IONS
|
$ 31.04
|
$ 4.44 B
|
$ -384 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![TG Therapeutics logo](/static/img/stocks/tgtx.png) |
TG Therapeutics
TGTX
|
$ 30.71
|
$ 4.36 B
|
$ -120 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Krystal Biotech logo](/static/img/stocks/krys.png) |
Krystal Biotech
KRYS
|
$ 153.24
|
$ 4.16 B
|
$ 4.05 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![PTC Therapeutics logo](/static/img/stocks/ptct.png) |
PTC Therapeutics
PTCT
|
$ 51.82
|
$ 3.88 B
|
$ -138 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Rigel Pharmaceuticals logo](/static/img/stocks/rigl.png) |
Rigel Pharmaceuticals
RIGL
|
$ 21.57
|
$ 3.75 B
|
$ 4.97 M
|
57.8
|
18.1
|
$ 0.3
|
![usa](/static/img/countries/usa.png) |
![SpringWorks Therapeutics logo](/static/img/stocks/swtx.png) |
SpringWorks Therapeutics
SWTX
|
$ 57.43
|
$ 3.63 B
|
$ -311 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![ADMA Biologics logo](/static/img/stocks/adma.png) |
ADMA Biologics
ADMA
|
$ 15.9
|
$ 3.56 B
|
$ 117 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Gracell Biotechnologies logo](/static/img/stocks/grcl.png) |
Gracell Biotechnologies
GRCL
|
$ 10.25
|
$ 3.37 B
|
∙ |
∙ |
∙ |
∙ |
![china](/static/img/countries/china.png) |
![Rhythm Pharmaceuticals logo](/static/img/stocks/rytm.png) |
Rhythm Pharmaceuticals
RYTM
|
$ 56.69
|
$ 3.27 B
|
$ -189 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Scholar Rock Holding Corporation logo](/static/img/stocks/srrk.png) |
Scholar Rock Holding Corporation
SRRK
|
$ 37.07
|
$ 3.09 B
|
$ -181 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Veracyte logo](/static/img/stocks/vcyt.png) |
Veracyte
VCYT
|
$ 41.11
|
$ 2.99 B
|
$ -1.28 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Dicerna Pharmaceuticals, Inc. logo](/static/img/stocks/drna.png) |
Dicerna Pharmaceuticals, Inc.
DRNA
|
$ 38.25
|
$ 2.98 B
|
$ -70.6 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Viela Bio, Inc. logo](/static/img/stocks/vie.png) |
Viela Bio, Inc.
VIE
|
$ 53.01
|
$ 2.91 B
|
$ 57.6 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Amicus Therapeutics logo](/static/img/stocks/fold.png) |
Amicus Therapeutics
FOLD
|
$ 9.77
|
$ 2.88 B
|
$ 9.53 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Viking Therapeutics logo](/static/img/stocks/vktx.png) |
Viking Therapeutics
VKTX
|
$ 30.48
|
$ 2.88 B
|
$ -122 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Translate Bio, Inc. logo](/static/img/stocks/tbio.png) |
Translate Bio, Inc.
TBIO
|
$ 37.36
|
$ 2.81 B
|
$ 86.2 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Immunovant logo](/static/img/stocks/imvt.png) |
Immunovant
IMVT
|
$ 20.33
|
$ 2.81 B
|
$ 324 K
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Vericel Corporation logo](/static/img/stocks/vcel.png) |
Vericel Corporation
VCEL
|
$ 57.09
|
$ 2.72 B
|
$ -14.2 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Denali Therapeutics logo](/static/img/stocks/dnli.png) |
Denali Therapeutics
DNLI
|
$ 21.37
|
$ 2.68 B
|
$ -385 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Akero Therapeutics logo](/static/img/stocks/akro.png) |
Akero Therapeutics
AKRO
|
$ 50.52
|
$ 2.66 B
|
$ -115 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Xenon Pharmaceuticals logo](/static/img/stocks/xene.png) |
Xenon Pharmaceuticals
XENE
|
$ 38.91
|
$ 2.6 B
|
$ -174 M
|
∙ |
∙ |
∙ |
![canada](/static/img/countries/canada.png) |
![Burford Capital Limited logo](/static/img/stocks/bur.png) |
Burford Capital Limited
BUR
|
$ 15.36
|
$ 2.6 B
|
∙ |
∙ |
∙ |
∙ |
![](/static/img/countries/.png) |
![Beam Therapeutics logo](/static/img/stocks/beam.png) |
Beam Therapeutics
BEAM
|
$ 32.4
|
$ 2.5 B
|
$ -402 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Catalyst Pharmaceuticals logo](/static/img/stocks/cprx.png) |
Catalyst Pharmaceuticals
CPRX
|
$ 23.27
|
$ 2.47 B
|
$ 117 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![BELLUS Health logo](/static/img/stocks/blu.png) |
BELLUS Health
BLU
|
$ 14.74
|
$ 2.47 B
|
∙ |
∙ |
∙ |
∙ |
![canada](/static/img/countries/canada.png) |
![Morphic Holding logo](/static/img/stocks/morf.png) |
Morphic Holding
MORF
|
$ 56.99
|
$ 2.42 B
|
$ -96.7 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Avidity Biosciences logo](/static/img/stocks/rna.png) |
Avidity Biosciences
RNA
|
$ 32.31
|
$ 2.36 B
|
$ -314 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Harmony Biosciences Holdings logo](/static/img/stocks/hrmy.png) |
Harmony Biosciences Holdings
HRMY
|
$ 38.98
|
$ 2.32 B
|
$ 218 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Certara logo](/static/img/stocks/cert.png) |
Certara
CERT
|
$ 14.19
|
$ 2.26 B
|
$ -58.8 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Protagonist Therapeutics logo](/static/img/stocks/ptgx.png) |
Protagonist Therapeutics
PTGX
|
$ 38.67
|
$ 2.2 B
|
$ 97.8 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Alpine Immune Sciences logo](/static/img/stocks/alpn.png) |
Alpine Immune Sciences
ALPN
|
$ 64.97
|
$ 2.17 B
|
$ -67.6 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Kymera Therapeutics logo](/static/img/stocks/kymr.png) |
Kymera Therapeutics
KYMR
|
$ 36.88
|
$ 2.15 B
|
$ -232 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Cidara Therapeutics logo](/static/img/stocks/cdtx.png) |
Cidara Therapeutics
CDTX
|
$ 23.94
|
$ 2.09 B
|
$ -5.84 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Ligand Pharmaceuticals Incorporated logo](/static/img/stocks/lgnd.png) |
Ligand Pharmaceuticals Incorporated
LGND
|
$ 120.0
|
$ 2.08 B
|
$ 124 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Merus N.V. logo](/static/img/stocks/mrus.png) |
Merus N.V.
MRUS
|
$ 40.2
|
$ 2.07 B
|
$ -160 M
|
∙ |
∙ |
∙ |
![niderland](/static/img/countries/niderland.png) |
![Mirum Pharmaceuticals logo](/static/img/stocks/mirm.png) |
Mirum Pharmaceuticals
MIRM
|
$ 50.04
|
$ 2.05 B
|
$ -68.7 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Crinetics Pharmaceuticals logo](/static/img/stocks/crnx.png) |
Crinetics Pharmaceuticals
CRNX
|
$ 35.21
|
$ 2.04 B
|
$ -206 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Can-Fite BioPharma Ltd. logo](/static/img/stocks/canf.png) |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.53
|
$ 1.96 B
|
∙ |
∙ |
∙ |
∙ |
![israel](/static/img/countries/israel.png) |
![Trillium Therapeutics Inc. logo](/static/img/stocks/tril.png) |
Trillium Therapeutics Inc.
TRIL
|
$ 18.44
|
$ 1.94 B
|
$ 3.56 M
|
∙ |
∙ |
∙ |
![canada](/static/img/countries/canada.png) |
![Agios Pharmaceuticals logo](/static/img/stocks/agio.png) |
Agios Pharmaceuticals
AGIO
|
$ 33.22
|
$ 1.89 B
|
$ -381 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Opthea Limited logo](/static/img/stocks/opt.png) |
Opthea Limited
OPT
|
$ 5.21
|
$ 1.83 B
|
∙ |
∙ |
∙ |
∙ |
![australia](/static/img/countries/australia.png) |
![Pandion Therapeutics, Inc. logo](/static/img/stocks/pand.png) |
Pandion Therapeutics, Inc.
PAND
|
$ 60.05
|
$ 1.77 B
|
∙ |
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Five Prime Therapeutics, Inc. logo](/static/img/stocks/fprx.png) |
Five Prime Therapeutics, Inc.
FPRX
|
$ 38.0
|
$ 1.77 B
|
$ 17.3 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![BioCryst Pharmaceuticals logo](/static/img/stocks/bcrx.png) |
BioCryst Pharmaceuticals
BCRX
|
$ 9.05
|
$ 1.74 B
|
$ -93.3 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Kadmon Holdings, Inc. logo](/static/img/stocks/kdmn.png) |
Kadmon Holdings, Inc.
KDMN
|
$ 9.5
|
$ 1.7 B
|
∙ |
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Dynavax Technologies Corporation logo](/static/img/stocks/dvax.png) |
Dynavax Technologies Corporation
DVAX
|
$ 12.82
|
$ 1.65 B
|
$ 147 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Constellation Pharmaceuticals, Inc. logo](/static/img/stocks/cnst.png) |
Constellation Pharmaceuticals, Inc.
CNST
|
$ 33.99
|
$ 1.63 B
|
$ -14 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Завод ДИОД logo](/static/img/stocks/diod.png) |
Завод ДИОД
DIOD
|
-
|
-
|
₽ 39.9 M
|
∙ |
∙ |
∙ |
![russia](/static/img/countries/russia.png) |
![Aligos Therapeutics logo](/static/img/stocks/algs.png) |
Aligos Therapeutics
ALGS
|
$ 23.67
|
$ 1.52 B
|
$ -86.5 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Фармсинтез logo](/static/img/stocks/life.png) |
Фармсинтез
LIFE
|
-
|
-
|
∙ |
∙ |
∙ |
∙ |
![russia](/static/img/countries/russia.png) |
![Tarsus Pharmaceuticals logo](/static/img/stocks/tars.png) |
Tarsus Pharmaceuticals
TARS
|
$ 50.22
|
$ 1.48 B
|
$ -136 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![MannKind Corporation logo](/static/img/stocks/mnkd.png) |
MannKind Corporation
MNKD
|
$ 5.42
|
$ 1.45 B
|
$ 57.5 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Fusion Pharmaceuticals logo](/static/img/stocks/fusn.png) |
Fusion Pharmaceuticals
FUSN
|
$ 21.55
|
$ 1.41 B
|
$ -102 M
|
∙ |
∙ |
∙ |
![canada](/static/img/countries/canada.png) |
![Arvinas logo](/static/img/stocks/arvn.png) |
Arvinas
ARVN
|
$ 18.31
|
$ 1.32 B
|
$ -261 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Ardelyx logo](/static/img/stocks/ardx.png) |
Ardelyx
ARDX
|
$ 5.79
|
$ 1.27 B
|
$ -97.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Pieris Pharmaceuticals logo](/static/img/stocks/pirs.png) |
Pieris Pharmaceuticals
PIRS
|
$ 13.6
|
$ 1.22 B
|
$ -42.5 M
|
∙ |
∙ |
∙ |
![germany](/static/img/countries/germany.png) |
![IDEAYA Biosciences logo](/static/img/stocks/idya.png) |
IDEAYA Biosciences
IDYA
|
$ 21.0
|
$ 1.21 B
|
$ -214 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Adaptive Biotechnologies Corporation logo](/static/img/stocks/adpt.png) |
Adaptive Biotechnologies Corporation
ADPT
|
$ 8.33
|
$ 1.2 B
|
$ -159 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Innoviva logo](/static/img/stocks/inva.png) |
Innoviva
INVA
|
$ 18.08
|
$ 1.18 B
|
$ 284 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Nurix Therapeutics logo](/static/img/stocks/nrix.png) |
Nurix Therapeutics
NRIX
|
$ 17.59
|
$ 1.18 B
|
$ -174 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Wave Life Sciences Ltd. logo](/static/img/stocks/wve.png) |
Wave Life Sciences Ltd.
WVE
|
$ 10.81
|
$ 1.15 B
|
$ -138 M
|
∙ |
∙ |
∙ |
![singapore](/static/img/countries/singapore.png) |
![Aurinia Pharmaceuticals logo](/static/img/stocks/auph.png) |
Aurinia Pharmaceuticals
AUPH
|
$ 7.79
|
$ 1.12 B
|
$ -13.5 M
|
∙ |
∙ |
∙ |
![canada](/static/img/countries/canada.png) |
![Immutep Limited logo](/static/img/stocks/immp.png) |
Immutep Limited
IMMP
|
$ 1.96
|
$ 1.08 B
|
∙ |
∙ |
∙ |
∙ |
![australia](/static/img/countries/australia.png) |
![Liquidia Corporation logo](/static/img/stocks/lqda.png) |
Liquidia Corporation
LQDA
|
$ 16.2
|
$ 1.05 B
|
$ -98.8 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Syndax Pharmaceuticals logo](/static/img/stocks/sndx.png) |
Syndax Pharmaceuticals
SNDX
|
$ 14.92
|
$ 1.05 B
|
$ -130 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![AlloVir logo](/static/img/stocks/alvr.png) |
AlloVir
ALVR
|
$ 9.9
|
$ 1.03 B
|
$ -173 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Aeglea BioTherapeutics logo](/static/img/stocks/agle.png) |
Aeglea BioTherapeutics
AGLE
|
$ 12.01
|
$ 1.01 B
|
$ -82.5 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Arcus Biosciences logo](/static/img/stocks/rcus.png) |
Arcus Biosciences
RCUS
|
$ 13.1
|
$ 969 M
|
$ -231 M
|
∙ |
∙ |
∙ |
![](/static/img/countries/.png) |
![Xencor logo](/static/img/stocks/xncr.png) |
Xencor
XNCR
|
$ 16.31
|
$ 952 M
|
$ -88.2 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Intellia Therapeutics logo](/static/img/stocks/ntla.png) |
Intellia Therapeutics
NTLA
|
$ 10.7
|
$ 950 M
|
$ -420 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![AbCellera Biologics logo](/static/img/stocks/abcl.png) |
AbCellera Biologics
ABCL
|
$ 3.27
|
$ 946 M
|
$ -282 M
|
∙ |
∙ |
∙ |
![canada](/static/img/countries/canada.png) |
![Replimune Group logo](/static/img/stocks/repl.png) |
Replimune Group
REPL
|
$ 14.1
|
$ 939 M
|
$ -236 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Atara Biotherapeutics logo](/static/img/stocks/atra.png) |
Atara Biotherapeutics
ATRA
|
$ 8.59
|
$ 910 M
|
$ -137 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Arcutis Biotherapeutics logo](/static/img/stocks/arqt.png) |
Arcutis Biotherapeutics
ARQT
|
$ 12.78
|
$ 886 M
|
$ -185 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Rocket Pharmaceuticals logo](/static/img/stocks/rckt.png) |
Rocket Pharmaceuticals
RCKT
|
$ 10.47
|
$ 880 M
|
$ -269 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Poseida Therapeutics logo](/static/img/stocks/pstx.png) |
Poseida Therapeutics
PSTX
|
$ 9.5
|
$ 857 M
|
$ -67.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Zealand Pharma A/S logo](/static/img/stocks/zeal.png) |
Zealand Pharma A/S
ZEAL
|
$ 17.47
|
$ 821 M
|
$ -348 M
|
∙ |
12.4
|
∙ |
![danmark](/static/img/countries/danmark.png) |
![bluebird bio logo](/static/img/stocks/blue.png) |
bluebird bio
BLUE
|
$ 7.27
|
$ 798 M
|
$ -235 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Avid Bioservices logo](/static/img/stocks/cdmo.png) |
Avid Bioservices
CDMO
|
$ 12.49
|
$ 789 M
|
$ -17.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![BiondVax Pharmaceuticals Ltd. logo](/static/img/stocks/bvxv.png) |
BiondVax Pharmaceuticals Ltd.
BVXV
|
$ 1.36
|
$ 768 M
|
∙ |
22.3
|
∙ |
$ 0.1
|
![israel](/static/img/countries/israel.png) |
![Prothena Corporation plc logo](/static/img/stocks/prta.png) |
Prothena Corporation plc
PRTA
|
$ 14.17
|
$ 754 M
|
$ -78.5 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![89bio logo](/static/img/stocks/default.png) |
89bio
ETNB
|
$ 10.57
|
$ 752 M
|
$ -137 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![AVROBIO logo](/static/img/stocks/avro.png) |
AVROBIO
AVRO
|
$ 16.8
|
$ 745 M
|
$ -50.8 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Viridian Therapeutics logo](/static/img/stocks/vrdn.png) |
Viridian Therapeutics
VRDN
|
$ 16.4
|
$ 734 M
|
$ -187 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Anavex Life Sciences Corp. logo](/static/img/stocks/avxl.png) |
Anavex Life Sciences Corp.
AVXL
|
$ 8.52
|
$ 711 M
|
$ -51.1 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Adaptimmune Therapeutics plc logo](/static/img/stocks/adap.png) |
Adaptimmune Therapeutics plc
ADAP
|
$ 0.58
|
$ 700 M
|
$ -126 M
|
∙ |
∙ |
∙ |
![britain](/static/img/countries/britain.png) |
![uniQure N.V. logo](/static/img/stocks/qure.png) |
uniQure N.V.
QURE
|
$ 14.18
|
$ 676 M
|
$ -229 M
|
∙ |
∙ |
∙ |
![niderland](/static/img/countries/niderland.png) |
![Zogenix, Inc. logo](/static/img/stocks/zgnx.png) |
Zogenix, Inc.
ZGNX
|
$ 11.85
|
$ 664 M
|
$ 23.7 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![IMARA logo](/static/img/stocks/imra.png) |
IMARA
IMRA
|
$ 6.32
|
$ 663 M
|
$ -102 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Mereo BioPharma Group plc logo](/static/img/stocks/mreo.png) |
Mereo BioPharma Group plc
MREO
|
$ 2.87
|
$ 660 M
|
∙ |
∙ |
∙ |
∙ |
![britain](/static/img/countries/britain.png) |
![Catabasis Pharmaceuticals, Inc. logo](/static/img/stocks/catb.png) |
Catabasis Pharmaceuticals, Inc.
CATB
|
$ 8.54
|
$ 657 M
|
$ 9.44 B
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Intercept Pharmaceuticals logo](/static/img/stocks/icpt.png) |
Intercept Pharmaceuticals
ICPT
|
$ 19.0
|
$ 643 M
|
$ -80.6 M
|
2.8
|
2.0
|
$ 6.8
|
![usa](/static/img/countries/usa.png) |
![Silence Therapeutics plc logo](/static/img/stocks/default.png) |
Silence Therapeutics plc
SLN
|
$ 4.84
|
$ 622 M
|
∙ |
∙ |
∙ |
∙ |
![britain](/static/img/countries/britain.png) |
![Sana Biotechnology logo](/static/img/stocks/sana.png) |
Sana Biotechnology
SANA
|
$ 3.16
|
$ 615 M
|
$ -208 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Kura Oncology logo](/static/img/stocks/kura.png) |
Kura Oncology
KURA
|
$ 8.28
|
$ 606 M
|
$ 1.23 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Praxis Precision Medicines logo](/static/img/stocks/prax.png) |
Praxis Precision Medicines
PRAX
|
$ 90.77
|
$ 599 M
|
$ -184 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Monopar Therapeutics logo](/static/img/stocks/default.png) |
Monopar Therapeutics
MNPR
|
$ 43.1
|
$ 596 M
|
$ -7.76 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Ocular Therapeutix logo](/static/img/stocks/ocul.png) |
Ocular Therapeutix
OCUL
|
$ 7.28
|
$ 581 M
|
$ -91.5 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Omeros Corporation logo](/static/img/stocks/omer.png) |
Omeros Corporation
OMER
|
$ 9.18
|
$ 576 M
|
$ -181 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![AnaptysBio logo](/static/img/stocks/anab.png) |
AnaptysBio
ANAB
|
$ 21.22
|
$ 571 M
|
$ -143 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Arbutus Biopharma Corporation logo](/static/img/stocks/abus.png) |
Arbutus Biopharma Corporation
ABUS
|
$ 3.29
|
$ 546 M
|
$ -66.9 M
|
∙ |
∙ |
∙ |
![canada](/static/img/countries/canada.png) |
![CorMedix logo](/static/img/stocks/crmd.png) |
CorMedix
CRMD
|
$ 10.48
|
$ 533 M
|
$ -33.1 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Urovant Sciences Ltd. logo](/static/img/stocks/urov.png) |
Urovant Sciences Ltd.
UROV
|
$ 16.24
|
$ 532 M
|
$ 2.76 B
|
∙ |
∙ |
∙ |
![britain](/static/img/countries/britain.png) |
![Theravance Biopharma logo](/static/img/stocks/tbph.png) |
Theravance Biopharma
TBPH
|
$ 9.61
|
$ 531 M
|
$ -131 M
|
∙ |
∙ |
∙ |
![cayman-islands](/static/img/countries/cayman-islands.png) |
![Frequency Therapeutics logo](/static/img/stocks/default.png) |
Frequency Therapeutics
FREQ
|
$ 14.98
|
$ 528 M
|
$ -76.7 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![MediWound Ltd. logo](/static/img/stocks/mdwd.png) |
MediWound Ltd.
MDWD
|
$ 18.76
|
$ 510 M
|
$ -42.7 M
|
∙ |
∙ |
∙ |
![israel](/static/img/countries/israel.png) |
![Xeris Pharmaceuticals logo](/static/img/stocks/xers.png) |
Xeris Pharmaceuticals
XERS
|
$ 3.59
|
$ 494 M
|
$ -31.8 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Relay Therapeutics logo](/static/img/stocks/rlay.png) |
Relay Therapeutics
RLAY
|
$ 4.0
|
$ 490 M
|
$ -350 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Arcturus Therapeutics Holdings logo](/static/img/stocks/arct.png) |
Arcturus Therapeutics Holdings
ARCT
|
$ 18.05
|
$ 481 M
|
$ -78.1 M
|
∙ |
∙ |
∙ |
![israel](/static/img/countries/israel.png) |
![Precigen logo](/static/img/stocks/pgen.png) |
Precigen
PGEN
|
$ 1.96
|
$ 479 M
|
$ 14.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Stoke Therapeutics logo](/static/img/stocks/stok.png) |
Stoke Therapeutics
STOK
|
$ 10.68
|
$ 470 M
|
$ -103 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Savara logo](/static/img/stocks/svra.png) |
Savara
SVRA
|
$ 2.82
|
$ 466 M
|
$ -89.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Bicycle Therapeutics plc logo](/static/img/stocks/bcyc.png) |
Bicycle Therapeutics plc
BCYC
|
$ 12.55
|
$ 447 M
|
$ -186 M
|
∙ |
∙ |
∙ |
![britain](/static/img/countries/britain.png) |
![XTL Biopharmaceuticals Ltd. logo](/static/img/stocks/xtlb.png) |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.74
|
$ 442 M
|
$ -520 K
|
∙ |
∙ |
∙ |
![israel](/static/img/countries/israel.png) |
![ChromaDex Corporation logo](/static/img/stocks/cdxc.png) |
ChromaDex Corporation
CDXC
|
$ 5.87
|
$ 440 M
|
$ -10.7 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![SIGA Technologies logo](/static/img/stocks/siga.png) |
SIGA Technologies
SIGA
|
$ 6.14
|
$ 438 M
|
$ 55.8 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Forte Biosciences logo](/static/img/stocks/default.png) |
Forte Biosciences
FBRX
|
$ 12.0
|
$ 436 M
|
$ -16.8 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![ORIC Pharmaceuticals logo](/static/img/stocks/oric.png) |
ORIC Pharmaceuticals
ORIC
|
$ 8.36
|
$ 430 M
|
$ -99.3 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Kezar Life Sciences logo](/static/img/stocks/kzr.png) |
Kezar Life Sciences
KZR
|
$ 5.89
|
$ 427 M
|
$ -93.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Capricor Therapeutics logo](/static/img/stocks/capr.png) |
Capricor Therapeutics
CAPR
|
$ 15.95
|
$ 427 M
|
$ -40.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Eton Pharmaceuticals logo](/static/img/stocks/eton.png) |
Eton Pharmaceuticals
ETON
|
$ 16.42
|
$ 421 M
|
$ -3.49 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![ARCA biopharma logo](/static/img/stocks/abio.png) |
ARCA biopharma
ABIO
|
$ 28.8
|
$ 415 M
|
$ -10 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Trevi Therapeutics logo](/static/img/stocks/trvi.png) |
Trevi Therapeutics
TRVI
|
$ 4.07
|
$ 403 M
|
$ -35.6 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Akebia Therapeutics logo](/static/img/stocks/akba.png) |
Akebia Therapeutics
AKBA
|
$ 2.13
|
$ 399 M
|
$ -7.26 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Cullinan Management logo](/static/img/stocks/cgem.png) |
Cullinan Management
CGEM
|
$ 9.53
|
$ 396 M
|
$ 104 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Chimerix logo](/static/img/stocks/cmrx.png) |
Chimerix
CMRX
|
$ 4.38
|
$ 388 M
|
$ -60.2 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Aldeyra Therapeutics logo](/static/img/stocks/aldx.png) |
Aldeyra Therapeutics
ALDX
|
$ 6.49
|
$ 383 M
|
$ -58.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![MeiraGTx Holdings plc logo](/static/img/stocks/mgtx.png) |
MeiraGTx Holdings plc
MGTX
|
$ 6.7
|
$ 378 M
|
$ -91.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![G1 Therapeutics logo](/static/img/stocks/gthx.png) |
G1 Therapeutics
GTHX
|
$ 7.15
|
$ 370 M
|
$ -16.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Altimmune logo](/static/img/stocks/alt.png) |
Altimmune
ALT
|
$ 6.37
|
$ 339 M
|
$ -86.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Allogene Therapeutics logo](/static/img/stocks/allo.png) |
Allogene Therapeutics
ALLO
|
$ 2.04
|
$ 320 M
|
$ -302 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![REGENXBIO logo](/static/img/stocks/rgnx.png) |
REGENXBIO
RGNX
|
$ 7.3
|
$ 319 M
|
$ -246 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Trean Insurance Group logo](/static/img/stocks/tig.png) |
Trean Insurance Group
TIG
|
$ 6.16
|
$ 316 M
|
$ 6 M
|
9.7
|
1.2
|
$ 0.6
|
![usa](/static/img/countries/usa.png) |
![UroGen Pharma Ltd. logo](/static/img/stocks/urgn.png) |
UroGen Pharma Ltd.
URGN
|
$ 10.77
|
$ 311 M
|
$ -82.1 M
|
∙ |
∙ |
∙ |
![israel](/static/img/countries/israel.png) |
![Revance Therapeutics logo](/static/img/stocks/rvnc.png) |
Revance Therapeutics
RVNC
|
$ 3.65
|
$ 309 M
|
$ -148 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Keros Therapeutics logo](/static/img/stocks/kros.png) |
Keros Therapeutics
KROS
|
$ 10.32
|
$ 304 M
|
$ -145 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Phathom Pharmaceuticals logo](/static/img/stocks/default.png) |
Phathom Pharmaceuticals
PHAT
|
$ 5.77
|
$ 296 M
|
$ -215 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Codexis logo](/static/img/stocks/cdxs.png) |
Codexis
CDXS
|
$ 4.31
|
$ 294 M
|
$ -78.2 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Cerecor Inc. logo](/static/img/stocks/cerc.png) |
Cerecor Inc.
CERC
|
$ 2.93
|
$ 283 M
|
$ 174 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Cara Therapeutics logo](/static/img/stocks/cara.png) |
Cara Therapeutics
CARA
|
$ 5.2
|
$ 282 M
|
$ -85.2 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Kodiak Sciences logo](/static/img/stocks/kod.png) |
Kodiak Sciences
KOD
|
$ 5.26
|
$ 276 M
|
$ -280 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Y-mAbs Therapeutics logo](/static/img/stocks/ymab.png) |
Y-mAbs Therapeutics
YMAB
|
$ 6.24
|
$ 272 M
|
$ -79.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Daré Bioscience logo](/static/img/stocks/dare.png) |
Daré Bioscience
DARE
|
$ 3.04
|
$ 265 M
|
$ -21.1 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![iTeos Therapeutics logo](/static/img/stocks/itos.png) |
iTeos Therapeutics
ITOS
|
$ 7.4
|
$ 265 M
|
$ -148 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![ZIOPHARM Oncology, Inc. logo](/static/img/stocks/ziop.png) |
ZIOPHARM Oncology, Inc.
ZIOP
|
$ 1.22
|
$ 264 M
|
$ 154 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Atea Pharmaceuticals logo](/static/img/stocks/avir.png) |
Atea Pharmaceuticals
AVIR
|
$ 3.15
|
$ 263 M
|
$ -160 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Anika Therapeutics logo](/static/img/stocks/anik.png) |
Anika Therapeutics
ANIK
|
$ 17.86
|
$ 262 M
|
$ -36.3 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Kamada Ltd. logo](/static/img/stocks/kmda.png) |
Kamada Ltd.
KMDA
|
$ 7.79
|
$ 260 M
|
$ 6.96 M
|
32.8
|
3.3
|
$ 0.1
|
![israel](/static/img/countries/israel.png) |
![Foghorn Therapeutics logo](/static/img/stocks/default.png) |
Foghorn Therapeutics
FHTX
|
$ 6.13
|
$ 257 M
|
$ -92.5 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Vanda Pharmaceuticals logo](/static/img/stocks/vnda.png) |
Vanda Pharmaceuticals
VNDA
|
$ 4.42
|
$ 257 M
|
$ -25.7 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![BioDelivery Sciences International logo](/static/img/stocks/bdsi.png) |
BioDelivery Sciences International
BDSI
|
$ 2.58
|
$ 255 M
|
$ 40.6 M
|
8.3
|
1.5
|
$ 0.3
|
![usa](/static/img/countries/usa.png) |
![MorphoSys AG logo](/static/img/stocks/mor.png) |
MorphoSys AG
MOR
|
$ 18.96
|
$ 254 M
|
∙ |
∙ |
∙ |
∙ |
![germany](/static/img/countries/germany.png) |
![EyePoint Pharmaceuticals logo](/static/img/stocks/eypt.png) |
EyePoint Pharmaceuticals
EYPT
|
$ 6.5
|
$ 253 M
|
$ -76.7 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Amarin Corporation plc logo](/static/img/stocks/amrn.png) |
Amarin Corporation plc
AMRN
|
$ 0.61
|
$ 249 M
|
$ -95.6 M
|
∙ |
∙ |
∙ |
![irlanda](/static/img/countries/irlanda.png) |
![Chiasma, Inc. logo](/static/img/stocks/chma.png) |
Chiasma, Inc.
CHMA
|
$ 3.76
|
$ 238 M
|
∙ |
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Rezolute logo](/static/img/stocks/default.png) |
Rezolute
RZLT
|
$ 4.61
|
$ 237 M
|
$ -57.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Innate Pharma S.A. logo](/static/img/stocks/ipha.png) |
Innate Pharma S.A.
IPHA
|
$ 1.95
|
$ 235 M
|
∙ |
∙ |
∙ |
∙ |
![france](/static/img/countries/france.png) |
![Corvus Pharmaceuticals logo](/static/img/stocks/crvs.png) |
Corvus Pharmaceuticals
CRVS
|
$ 4.88
|
$ 234 M
|
$ -24.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![AC Immune SA logo](/static/img/stocks/aciu.png) |
AC Immune SA
ACIU
|
$ 2.74
|
$ 229 M
|
$ -49.6 M
|
∙ |
28.0
|
∙ |
![schweiz](/static/img/countries/schweiz.png) |
![Olema Pharmaceuticals logo](/static/img/stocks/olma.png) |
Olema Pharmaceuticals
OLMA
|
$ 4.97
|
$ 225 M
|
$ -120 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Merrimack Pharmaceuticals logo](/static/img/stocks/mack.png) |
Merrimack Pharmaceuticals
MACK
|
$ 15.13
|
$ 216 M
|
$ -1.65 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Gritstone Oncology logo](/static/img/stocks/grts.png) |
Gritstone Oncology
GRTS
|
$ 2.39
|
$ 213 M
|
$ -134 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Immunome logo](/static/img/stocks/imnm.png) |
Immunome
IMNM
|
$ 10.4
|
$ 206 M
|
$ -154 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![DiaMedica Therapeutics logo](/static/img/stocks/dmac.png) |
DiaMedica Therapeutics
DMAC
|
$ 6.29
|
$ 205 M
|
$ -17.7 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Tonix Pharmaceuticals Holding Corp. logo](/static/img/stocks/tnxp.png) |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 11.95
|
$ 204 M
|
$ -139 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Aquestive Therapeutics logo](/static/img/stocks/aqst.png) |
Aquestive Therapeutics
AQST
|
$ 3.32
|
$ 203 M
|
$ -18.8 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![KemPharm logo](/static/img/stocks/kmph.png) |
KemPharm
KMPH
|
$ 5.81
|
$ 200 M
|
$ -64.1 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Gossamer Bio logo](/static/img/stocks/goss.png) |
Gossamer Bio
GOSS
|
$ 1.31
|
$ 200 M
|
$ -63.1 M
|
∙ |
1.3
|
∙ |
![usa](/static/img/countries/usa.png) |
![Compugen Ltd. logo](/static/img/stocks/cgen.png) |
Compugen Ltd.
CGEN
|
$ 2.22
|
$ 195 M
|
∙ |
∙ |
8.9
|
∙ |
![israel](/static/img/countries/israel.png) |
![Cardiff Oncology logo](/static/img/stocks/crdf.png) |
Cardiff Oncology
CRDF
|
$ 4.29
|
$ 192 M
|
$ -42.1 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Taysha Gene Therapies logo](/static/img/stocks/tsha.png) |
Taysha Gene Therapies
TSHA
|
$ 1.63
|
$ 189 M
|
$ -86.6 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![KalVista Pharmaceuticals logo](/static/img/stocks/kalv.png) |
KalVista Pharmaceuticals
KALV
|
$ 9.76
|
$ 186 M
|
$ -108 M
|
∙ |
∙ |
∙ |
![britain](/static/img/countries/britain.png) |
![I-Mab logo](/static/img/stocks/imab.png) |
I-Mab
IMAB
|
$ 0.96
|
$ 184 M
|
∙ |
∙ |
∙ |
∙ |
![china](/static/img/countries/china.png) |
![Voyager Therapeutics logo](/static/img/stocks/vygr.png) |
Voyager Therapeutics
VYGR
|
$ 4.23
|
$ 182 M
|
$ 109 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Protalix BioTherapeutics logo](/static/img/stocks/plx.png) |
Protalix BioTherapeutics
PLX
|
$ 2.69
|
$ 182 M
|
$ -11.1 M
|
5.2
|
1.2
|
$ 0.3
|
![israel](/static/img/countries/israel.png) |
![Pliant Therapeutics logo](/static/img/stocks/plrx.png) |
Pliant Therapeutics
PLRX
|
$ 3.04
|
$ 179 M
|
$ -221 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Fennec Pharmaceuticals logo](/static/img/stocks/fenc.png) |
Fennec Pharmaceuticals
FENC
|
$ 6.68
|
$ 178 M
|
$ -20.6 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Ocugen logo](/static/img/stocks/ocgn.png) |
Ocugen
OCGN
|
$ 0.72
|
$ 176 M
|
$ -71.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Biophytis SA logo](/static/img/stocks/bpts.png) |
Biophytis SA
BPTS
|
$ 8.22
|
$ 169 M
|
∙ |
∙ |
∙ |
∙ |
![france](/static/img/countries/france.png) |
![INmune Bio logo](/static/img/stocks/inmb.png) |
INmune Bio
INMB
|
$ 9.18
|
$ 165 M
|
$ -37.1 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Progenity, Inc. logo](/static/img/stocks/prog.png) |
Progenity, Inc.
PROG
|
$ 0.88
|
$ 164 M
|
∙ |
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Aclaris Therapeutics logo](/static/img/stocks/acrs.png) |
Aclaris Therapeutics
ACRS
|
$ 2.33
|
$ 163 M
|
$ -73 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Greenwich LifeSciences logo](/static/img/stocks/glsi.png) |
Greenwich LifeSciences
GLSI
|
$ 12.38
|
$ 159 M
|
$ -10.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Zentalis Pharmaceuticals logo](/static/img/stocks/zntl.png) |
Zentalis Pharmaceuticals
ZNTL
|
$ 2.43
|
$ 159 M
|
$ -203 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![MacroGenics logo](/static/img/stocks/mgnx.png) |
MacroGenics
MGNX
|
$ 2.56
|
$ 159 M
|
$ -152 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![C4 Therapeutics logo](/static/img/stocks/cccc.png) |
C4 Therapeutics
CCCC
|
$ 3.18
|
$ 158 M
|
$ -108 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![La Jolla Pharmaceutical Company logo](/static/img/stocks/ljpc.png) |
La Jolla Pharmaceutical Company
LJPC
|
$ 6.2
|
$ 154 M
|
$ 1.73 M
|
9.0
|
3.1
|
$ 0.7
|
![usa](/static/img/countries/usa.png) |
![Acasti Pharma logo](/static/img/stocks/acst.png) |
Acasti Pharma
ACST
|
$ 3.37
|
$ 150 M
|
$ -18.6 M
|
∙ |
∙ |
∙ |
![canada](/static/img/countries/canada.png) |
![Champions Oncology logo](/static/img/stocks/default.png) |
Champions Oncology
CSBR
|
$ 11.07
|
$ 150 M
|
$ -669 K
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Larimar Therapeutics logo](/static/img/stocks/default.png) |
Larimar Therapeutics
LRMR
|
$ 3.34
|
$ 147 M
|
$ -41 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Alector logo](/static/img/stocks/alec.png) |
Alector
ALEC
|
$ 1.7
|
$ 142 M
|
$ -125 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![scPharmaceuticals logo](/static/img/stocks/scph.png) |
scPharmaceuticals
SCPH
|
$ 3.68
|
$ 142 M
|
$ -63.2 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Fate Therapeutics logo](/static/img/stocks/fate.png) |
Fate Therapeutics
FATE
|
$ 1.42
|
$ 140 M
|
$ -257 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Inventiva S.A. logo](/static/img/stocks/iva.png) |
Inventiva S.A.
IVA
|
$ 2.51
|
$ 138 M
|
∙ |
∙ |
∙ |
∙ |
![france](/static/img/countries/france.png) |
![Strongbridge Biopharma plc logo](/static/img/stocks/sbbp.png) |
Strongbridge Biopharma plc
SBBP
|
$ 2.0
|
$ 136 M
|
$ 1.52 B
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Puma Biotechnology logo](/static/img/stocks/pbyi.png) |
Puma Biotechnology
PBYI
|
$ 2.86
|
$ 135 M
|
$ 29.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Matinas BioPharma Holdings logo](/static/img/stocks/mtnb.png) |
Matinas BioPharma Holdings
MTNB
|
$ 0.61
|
$ 133 M
|
$ -22.1 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Verastem logo](/static/img/stocks/vstm.png) |
Verastem
VSTM
|
$ 5.97
|
$ 132 M
|
$ -86.3 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Abeona Therapeutics logo](/static/img/stocks/abeo.png) |
Abeona Therapeutics
ABEO
|
$ 6.02
|
$ 129 M
|
$ -56.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Sesen Bio logo](/static/img/stocks/sesn.png) |
Sesen Bio
SESN
|
$ 0.63
|
$ 127 M
|
$ -62.9 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Galecto logo](/static/img/stocks/default.png) |
Galecto
GLTO
|
$ 4.78
|
$ 127 M
|
$ -23.5 M
|
∙ |
∙ |
∙ |
![danmark](/static/img/countries/danmark.png) |
![Selecta Biosciences logo](/static/img/stocks/selb.png) |
Selecta Biosciences
SELB
|
$ 0.87
|
$ 126 M
|
$ -29.4 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |
![Lineage Cell Therapeutics logo](/static/img/stocks/lctx.png) |
Lineage Cell Therapeutics
LCTX
|
$ 0.69
|
$ 119 M
|
$ -22.5 M
|
∙ |
∙ |
∙ |
![usa](/static/img/countries/usa.png) |